Is BrightSpring Health Services, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for BrightSpring Health Services, Inc. has moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued, supported by a P/E ratio of 37, a PEG ratio of 0.12, and an EV to EBITDA ratio of 12.65, which suggest that the stock is priced attractively relative to its growth potential and earnings.
In comparison to its peer, BrightSpring's P/E ratio of 37.784 is slightly higher than the industry average, but its PEG ratio of 0.0924 indicates strong growth prospects relative to its price. The company has significantly outperformed the S&P 500 over various periods, with a year-to-date return of 74.57% compared to the S&P 500's 13.30%, and a one-year return of 86.86% against 14.08%. This strong performance reinforces the notion that BrightSpring Health Services is currently undervalued.